Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

This section has resources that you may require for your formulary submissions and business cases or policy reviews. As well as product information, therapy support resources and treatment guidelines. You can download these materials to better support your decision making.

Dermatology

document-icon

Dupixent® (dupilumab) Formulary Application Support Pack


This document provides factual and technical information about Dupixent to support you with relevant document for local formulary applications.

Dupixent® (dupilumab) Optimisation Model


The impact on resource utilisation when using Dupixent in accordance with the SmPC.

Diabetes

Trurapi®▼ (insulin aspart 100 units/mL)


Simulate your savings from switching to Trurapi.

lighthouse-icon

Looking for something else?

We have a range of cost models available. If you need a more detailed modelling of our basal and rapid acting insulins portfolio, please reach out to one of our representatives.

Respiratory

COPD - Eligible Population Estimator


This document provides information on estimating patients who might be eligable for Dupixent® via the COPD indication.

COPD - Burden Analysis Model


Explore the impact that biologics could have on COPD services in regard to costs, admissions and stays within hospital.

Burden of COPD Infographic


An infographic showing the burden of COPD on hospital admissions, bed days and length of stay in England. For data relating to your ICB, please Get in Touch via the link below.

line gray
Get in Touch with the Health System Solutions Team

MAT-XU-2401933 (v2.0) Date of Preparation: October 2025